Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 3.53% is 102% above its 2-year average of -184.56%, near the high end of its 2-year range (-687.10%–3.53%).
101.57% above its 12-month average of -225.06%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2024 (2024-12-31): -66.61%.
EBITDA MARGIN
3.53%
EBITDA MARGIN AVG TTM
-225.06%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+101.57%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$3.42M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.52M
EBITDA Margin
-2774.55%
TTM Avg
-3680.87%
3Y Avg
-3159.91%
5Y Avg
-3026.36%
Market Cap
$3.23M
EBITDA Margin
-7.62%
TTM Avg
-1345.01%
3Y Avg
-903.09%
5Y Avg
-551.32%
Market Cap
$3.79M
EBITDA Margin
-334.54%
TTM Avg
-323.48%
3Y Avg
-700.81%
5Y Avg
-1335.84%
Market Cap
$3.22M
EBITDA Margin
-2030.10%
TTM Avg
-2765.29%
3Y Avg
-1907.45%
5Y Avg
-2238.98%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moolec Science S.A. (MLEC) | $3.46M | 3.53% | -225.06% | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.50M | N/A | N/A | N/A | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.42M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.61M | N/A | N/A | N/A | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.52M | -2774.55% | -3680.87% | -3159.91% | -3026.36% |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.23M | -7.62% | -1345.01% | -903.09% | -551.32% |
| Evogene Ltd. (EVGN)vs › | $3.79M | -334.54% | -323.48% | -700.81% | -1335.84% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.22M | -2030.10% | -2765.29% | -1907.45% | -2238.98% |
| MBody AI Ltd. (MBAI)vs › | $3.17M | N/A | N/A | N/A | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.14M | -437.97% | -452.41% | -479.95% | -376.71% |
Gross Margin
34.2%
EBITDA Margin
3.5%
Operating Margin
-3.1%
Net Margin
-105.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2024-12-31 | -66.61% |
| 2024-09-30 | -114.12% |
| 2024-06-30 | -174.41% |
| 2024-03-31 | -83.06% |
| 2023-12-31 | -687.10% |
| 2023-09-30 | -119.39% |
| 2023-06-30 | -47.25% |
